Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):259–266. doi: 10.1097/QAI.0b013e3181989a8b

Figure 1.

Figure 1

Rate of progression to composite endpoint of CD4+ ≤350, initiation of antiretroviral therapy or death for patients with R5 or D/M-tropic virus at baseline. Results are stratified for tertile of baseline CD4+ (≤ 547, 548–733 and ≥ 734 cells/μL).